MPS reports personal fees from Merck, Biogen, Sanofi, Novartis, Roche, GeNeuro, Medday, Celgene, Amgen, and Immunic, outside the submitted work, and reports grants from Roche, Novartis, and Biogen. In the past 36 months, EW received company honorarium for consulting from Emerald Pharmaceuticals, DBV, and Jazz Pharma. EW is site Principle Investigator for trials with Biogen, Alexion, and Roche, and volunteers on an advisory board for a Novartis trial. EW is a non-remunerated advisor for clinical trial design to Novartis, Biogen-IDEC, Sanofi, Genentech, Serono, and Celgene, and has has received funding from the National Institute of Health, National Muliple Sclerosis Society, Patient-Centered Outcomes Research Institute, Consortium of Multiple Sclerosis Centers, and the Race to Erase MS. We received no financial support for the research, authorship, or publication of this Comment.